Wordt geladen...
Spheramine for treatment of Parkinson’s disease
Spheramine (Bayer Schering Pharma AG, Berlin, Germany) is currently being tested as a new approach for the treatment of Parkinson’s disease (PD). It consists of an active component of cultured human retinal pigment epithelial (hRPE) cells, attached to an excipient part of crosslinked porcine gelatin...
Bewaard in:
| Gepubliceerd in: | Neurotherapeutics |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer-Verlag
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084167/ https://ncbi.nlm.nih.gov/pubmed/18394567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nurt.2008.02.006 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|